Hostname: page-component-84b7d79bbc-2l2gl Total loading time: 0 Render date: 2024-07-26T14:15:50.172Z Has data issue: false hasContentIssue false
  • English
  • Français

Comorbidity of parkinsonism and schizophrenia in a patient treated with clozapine

Published online by Cambridge University Press:  16 April 2020

A. Urban ,
J. Libiger ,
L. Hosák  and
K. Kupka
A. Urban*
Affiliation:
Department of Psychiatry, University Hospital, 500 05Hradec Králové, Czech Republic
J. Libiger
Affiliation:
Department of Psychiatry, University Hospital, 500 05Hradec Králové, Czech Republic
L. Hosák
Affiliation:
Department of Psychiatry, University Hospital, 500 05Hradec Králové, Czech Republic
K. Kupka
Affiliation:
Institute of Nuclear Medicine, Charles University, 1st School of Medicine, Prague, Czech Republic
*
2Corresponding author. urban@fnhk.cz
Get access

Abstract

Clozapine is the least likely anti-psychotic to induce extrapyramidal symptoms (EPS). We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS. Single photon emission computed tomography (SPECT) revealed a low density of presynaptic dopamine transporters in our patient's brain. A comorbid diagnosis of Parkinson's disease in schizophrenia was confirmed in this way. This helped us to find a proper therapeutic strategy for our patient.

Keywords

SchizophreniaParkinsonismClozapineSPECT
Type
Case report
Information
European Psychiatry , Volume 18 , Issue 5 , August 2003 , pp. 258 - 259
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gerlach, J, Lublin, H, Peacock, L.Extrapyramidal symptoms during long-term treatment with antipsychotics, special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology 1996;14:35S-9S.10.1016/0893-133X(95)00203-PCrossRefGoogle ScholarPubMed
Laakso, A, Bergman, J, Haaparanta, M, Vilkman, H, Solin, O, Syvalahti, E, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001;52:115–20.10.1016/S0920-9964(00)00095-5CrossRefGoogle ScholarPubMed
Laruelle, M, Abi-Dargham, A, van Dyck, C., Gil, R, D’Souza, DC, Krystal, J, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT. Biol Psychiatry 2000;47:371–9.10.1016/S0006-3223(99)00257-7CrossRefGoogle ScholarPubMed
Lavalaye, J, Linszen, DH, Booij, J, Dingemans, PM, Reneman, L, Habraken, JB, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizophr Res 2001;47:59–67.10.1016/S0920-9964(00)00023-2CrossRefGoogle Scholar
Schwarz, J, Scherer, J, Trenkwalder, C, Mozley, PD, Tatsch, K.Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Res 1998;83:23–8.10.1016/S0925-4927(98)00026-2CrossRefGoogle ScholarPubMed
Spivak, M, Mester, R, Abesgaus, J, Winterberg, N, Adlersberg, S, Gonen, N, et al. Clozapine treatment for neuroleptic-induced dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318–22.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.